HM Payson & Co’s Editas Medicine EDIT Stock Holding History

HM Payson & Co’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$681	Hold	210	–	–	﹤0.01%	1105
2026 Q1	$519	Hold	210	–	–	﹤0.01%	1092
2025 Q4	$431	Sell	210 -25	-11%	-$72	﹤0.01%	1123
2025 Q3	$816	Buy	235 +25	+12%	+$70	﹤0.01%	1057
2025 Q2	$462	Hold	210	–	–	﹤0.01%	972
2025 Q1	$244	Hold	210	–	–	﹤0.01%	1021
2024 Q4	$267	Hold	210	–	–	﹤0.01%	1014
2024 Q3	$717	Hold	210	–	–	﹤0.01%	1045
2024 Q2	$981	Hold	210	–	–	﹤0.01%	953
2024 Q1	$1.56K	Hold	210	–	–	﹤0.01%	911
2023 Q4	$2.13K	Hold	210	–	–	﹤0.01%	903
2023 Q3	$1.64K	Hold	210	–	–	﹤0.01%	943
2023 Q2	$1.73K	Hold	210	–	–	﹤0.01%	931
2023 Q1	$1.52K	Hold	210	–	–	﹤0.01%	942
2022 Q4	$1.86K	Hold	210	–	–	﹤0.01%	861
2022 Q3	$3K	Hold	210	–	–	﹤0.01%	884
2022 Q2	$2K	Hold	210	–	–	﹤0.01%	953
2022 Q1	$4K	Hold	210	–	–	﹤0.01%	924
2021 Q4	$6K	Hold	210	–	–	﹤0.01%	922
2021 Q3	$9K	Buy	+210	New	+$11.5K	﹤0.01%	840

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HM Payson & Co's EDIT Position: Q2 2026 in Review

HM Payson & Co held its Editas Medicine (EDIT) position steady in Q2 2026 at 210 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #1105.

HM Payson & Co first reported a position in EDIT in Q3 2021 and has held it in 20 quarters since. The position peaked at $9K in Q3 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

HM Payson & Co held 210 shares of Editas Medicine worth $681 as of Q2 2026.
HM Payson & Co left its Editas Medicine share count unchanged in Q2 2026.
Editas Medicine made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #1105 holding.
HM Payson & Co first reported a position in Editas Medicine in Q3 2021 and has held it in 20 quarters since.
HM Payson & Co's Editas Medicine position peaked at $9K in Q3 2021.
214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.